TABLE 1.
Patient Characteristics in Training and Validation Group
| Level | Training Group (n = 536) | Validation Group (n = 121) | P |
|---|---|---|---|
| ISS, % | |||
| 1 | 195 (37.3) | 41 (33.9) | .6842 |
| 2 | 174 (33.3) | 45 (37.2) | |
| 3 | 154 (29.4) | 35 (28.9) | |
| R-ISS, % | |||
| 1 | 145 (27.3) | 28 (23.1) | .6581 |
| 2 | 312 (58.6) | 75 (62.0) | |
| 3 | 75 (14.1) | 18 (14.9) | |
| R2-ISS, % | |||
| 1 | 111 (21.4) | 17 (14.0) | .06 |
| 2 | 146 (28.2) | 43 (35.5) | |
| 3 | 227 (43.8) | 48 (39.7) | |
| 4 | 34 (6.6) | 13 (10.7) | |
| Mayo-2022-score, % | |||
| I | 170 (33.1) | 38 (31.7) | .54 |
| II | 179 (34.8) | 48 (40.0) | |
| III | 165 (32.1) | 34 (28.3) | |
| Elevated LDH, % | |||
| No | 432 (81.5) | 92 (76.0) | .203 |
| Yes | 98 (18.5) | 29 (24.0) | |
| Gain 1q21, % | |||
| No | 312 (59.1) | 72 (59.5) | .965 |
| 3 copies | 162 (30.7) | 38 (31.4) | |
| >3 copies | 54 (10.2) | 11 (9.1) | |
| del17p13, % | |||
| No | 475 (88.6) | 107 (88.4) | 1 |
| Yes | 61 (11.4) | 14 (11.6) | |
| t(4;14), % | |||
| No | 473 (88.4) | 111 (91.7) | .3367 |
| Yes | 62 (11.6) | 10 (8.3) | |
| t(14;16), % | |||
| No | 516 (97.0) | 118 (98.3) | .5499 |
| Yes | 16 (3.0) | 2 (1.7) | |
| IgA, % | |||
| No | 423 (78.9) | 94 (77.7) | .8059 |
| Yes | 113 (21.1) | 27 (22.3) | |
| Creatinine >2 g/dL, % | |||
| No | 472 (88.1) | 107 (88.4) | 1 |
| Yes | 64 (11.9) | 14 (11.6) | |
| Age, years, median (IQR) | 58.00 (52.27 to 64.00) | 58.00 (54.00 to 66.00) | .2391 |
| UAMS70, median (IQR) | −0.15 (−0.58 to 0.27) | −0.28 (−0.65 to 0.26) | .3915 |
| GPI50, median (IQR) | 148.94 (102.01 to 210.16) | 140.18 (98.58 to 198.46) | .4454 |
Abbreviations: IgA, immunoglobulin A; LDH, lactate dehydrogenase; (R-) ISS, (revised) International Staging System.